共 16 条
[1]
Kaufmann M(2003)International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations J Clin Oncol 21 2600-2608
[2]
von Minckwitz G(1997)Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483-2493
[3]
Smith R(1999)Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460-469
[4]
Fisher B(1999)Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer J Clin Oncol 17 3058-3063
[5]
Brown A(2001)Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study J Clin Oncol 19 3506-3515
[6]
Mamounas E(undefined)undefined undefined undefined undefined-undefined
[7]
Wieand S(undefined)undefined undefined undefined undefined-undefined
[8]
Kuerer HM(undefined)undefined undefined undefined undefined-undefined
[9]
Newman LA(undefined)undefined undefined undefined undefined-undefined
[10]
Smith TM(undefined)undefined undefined undefined undefined-undefined